Upload
others
View
4
Download
0
Embed Size (px)
Citation preview
Last modified: 26/05/15 Guidelines for the Conduct of Registry Studies v4
EBMT
European Group for Blood and Marrow Transplantation
GUIDELINES FOR THE CONDUCT OF
REGISTRY BASED STUDIES
USING THE
EBMT DATABASE
CONDUCT OF REGISTRY STUDIES
TABLE OF CONTENTS
1 Registry studies ............................................................................................................2
2 An EBMT study ...........................................................................................................2
3 Types of Registry studies .............................................................................................2 3.1 Retrospective ...................................................................................................................................... 3
3.1.1 Data collection........................................................................................................................... 3 3.2 Prospective ......................................................................................................................................... 3
3.2.1 Clinical trials ............................................................................................................................. 3 3.2.1.1 EBMT sponsorship ............................................................................................................................... 3 3.2.1.2 Data collection ..................................................................................................................................... 3
3.2.2 Non interventional prospective studies ........................................................................................ 4 3.2.2.1 Non interventional prospective studies versus retrospective studies ........................................................ 4 3.2.2.2 Non interventional prospective studies versus clinical trials ................................................................... 5 3.2.2.3 Data collection in non interventional prospective studies........................................................................ 5
4 Procedures for Registry studies...................................................................................5 4.1 Initiator ............................................................................................................................................... 5 4.2 Concept .............................................................................................................................................. 6
4.2.1 Inter WP studies ......................................................................................................................... 6 4.3 Study protocol ..................................................................................................................................... 6
4.3.1 Population ................................................................................................................................. 7 4.3.2 Objective ................................................................................................................................... 7 4.3.3 Variables ................................................................................................................................... 7 4.3.4 Participants ............................................................................................................................... 7
4.3.4.1 Centre eligibility for non interventional prospective studies ................................................................... 8 4.3.5 Ethical committee approval ........................................................................................................ 8 4.3.6 Patient consent........................................................................................................................... 8 4.3.7 Time frame ................................................................................................................................. 9 4.3.8 Statistics .................................................................................................................................... 9 4.3.9 Authors ...................................................................................................................................... 9
4.4 Preliminary analysis ............................................................................................................................ 9
5 Administration .............................................................................................................9 5.1 Staffing ............................................................................................................................................... 9 5.2 Documentation .................................................................................................................................. 10 5.3 Budget .............................................................................................................................................. 10
5.3.1 External funding ...................................................................................................................... 10 5.4 Insurance .......................................................................................................................................... 10
6 Data collection ............................................................................................................ 11 6.1 Data collection and integrated National Registries ............................................................................. 11 6.2 Centre availability ............................................................................................................................. 11 6.3 Forms for data collection ................................................................................................................... 12 6.4 Existing data ..................................................................................................................................... 13 6.5 Requesting data ................................................................................................................................. 13
6.5.1 Requesting data from centres not performing data entry directly into the EBMT database ......... 14 6.5.2 Requesting data from centres performing data entry directly into the EBMT database ............... 14
6.5.2.1 Retrospective data .............................................................................................................................. 14 6.5.2.2 Prospective data ................................................................................................................................. 15
6.6 Entering data ..................................................................................................................................... 15
7 Procedures for statistical analysis of Registry studies. ............................................. 16
8 Authorship and acknowledgement guidelines .......................................................... 17
9 Requesting data from centres in countries with national registries. ........................ 17
10 Step by step procedure .............................................................................................. 17 10.1 First step: requesting participation ................................................................................................. 17
CONDUCT OF REGISTRY STUDIES
10.1.1 Documents needed ............................................................................................................... 17 10.1.2 Sending documents .............................................................................................................. 18 10.1.3 Following up participation request ...................................................................................... 18
10.2 Second step: requesting data ......................................................................................................... 18 10.2.1 Sending data request ........................................................................................................... 18
10.2.1.1 Retrospective data, including data needed for non interventional prospective studies ....................... 19 10.2.1.2 Prospective data ............................................................................................................................ 19
10.2.2 Following up data request ................................................................................................... 19 10.3 Study completion .......................................................................................................................... 19 10.4 Study page examples .................................................................................................................... 20
10.4.1 Retrospective study .............................................................................................................. 20 10.4.2 Non interventional prospective study .................................................................................... 21
10.5 Recommended flow and deadlines ................................................................................................ 22 10.5.1 Retrospective studies ........................................................................................................... 22 10.5.2 Non interventional prospective studies ................................................................................. 23
11 Contributors............................................................................................................... 24
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 2
1 Registry studies
One major goal when collecting data on patients whose treatment includes
haematopoietic stem cell transplantation is to make it possible to perform studies. During the
last 30 years many such studies have been run and published in major journals through the
work of a large number of EBMT investigators. The key structure for the performance of
registry studies are the EBMT Working parties (WPs). However, the EBMT structure and the
structure of data collection from EBMT centres have become increasingly complex and
EBMT member centres are under pressure to submit data, which is always complex and
sometimes bulky. It is essential that EBMT WPs follow certain rules when preparing registry
studies to ensure that centres are not overburdened by continuous and overlapping requests.
At the same time, there is a need to utilise the EBMT resources and the resources from the
contributing transplant centres in the most efficient way. The aim of this document is to
present guidelines on how such studies should be performed to further improve the way in
which registry studies are designed, carried out, analysed and reported.
2 An EBMT study
An EBMT registry study has to be initiated by an EBMT member and approved by at
least one EBMT WP. This person will be responsible for the design, collection, cleaning and
analyses of the data and its subsequent publication. If more than one WP is involved, it is the
responsibility of the chairperson of the proposing WP to inform the chairperson of those
other WPs involved in the proposed study.
Recently, the EBMT has created a series of committees (Cell Therapy, Cord Blood,
etc.) which also have an interest in study data. The heads of these committees should be
consulted if the study being proposed overlaps with their remit.
If an EBMT study originates outside of a WP or committee, the Registry Head can
advise on which WP chairpersons should be contacted for approval of the study or, if
necessary, forward the request to the EBMT Board.
3 Types of Registry studies
There are two types of studies which can be performed using the infrastructure of the
Registry:
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 3
3.1 Retrospective
A retrospective study uses information on events that have taken place in the past. In
most cases some or most of the data has already been gathered and stored in the registry.
However and also in most cases, new data, but always on past events, may have to be
requested.
3.1.1 Data collection
All data collected should be aimed to be stored in the Registry where possible (see
below).
3.2 Prospective
A prospective study is initiated before the events which will constitute the end points
of the study have taken place. Within this category there are two types of studies which need
to be clearly differentiated:
3.2.1 Clinical trials
If the protocol of a prospective study makes requirements that will affect the
management of the patient, whether in terms of the treatment itself or the investigations
required to obtain the necessary data, the study forms part of what is called “Prospective
Clinical Trials”. Clinical trials are complex to set up and carry with them a series of legal
requirements that require expert management.
3.2.1.1 EBMT sponsorship
All clinical trials must have a named sponsor which takes on legal responsibility. All
clinical trials to be sponsored by the EBMT must be approved by the EBMT before they can
be initiated and the necessary documentation and signatures must be in place.
All investigators wishing to conduct a clinical trial within the EBMT should refer
themselves to the Clinical Trials group for information and support.
3.2.1.2 Data collection
An important difference for the EBMT is that the data collected during the running of a
clinical trial must only be stored in the clinical trials database, although routine MED-AB can
and should still be stored in the Registry database. In some cases, fields that may reveal the
trial treatment should be left empty until the trial has closed. Advice should be sought from
the Registry Office in these cases.
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 4
3.2.2 Non interventional prospective studies
Non interventional prospective studies are prospective studies which are set up to
investigate events that will take place after the study has been initiated. The main and very
important difference between a clinical trial and a non interventional prospective study is that
the data collection or patient-participation in the non interventional study does not interfere
with the choice of treatment, sample collection, procedures, and the treatment itself, which
should entirely follow standard hospital practices.
Typically a non interventional prospective study behaves like a “fly on the wall” and
will aim to collect information on how different centres deal with the same problem or type
of patient. A non interventional prospective protocol cannot in any way set up conditions
modifying either the treatment of the patient or the number or type of investigations the
patient needs to be subjected to. It excludes the possibility of determining which treatment
protocol should be used, randomisation or other types of patient allocation to a specific
treatment, specified sample collection schedules, or collection of additional samples not
included in the centre’s routine procedures.
If there is the intention of collecting additional data through patient questionnaires or
scheduled sample collection which are outside the normal routine of the centre, the protocol
should be referred to the Clinical Trials group for advice.
Sometimes it is difficult to judge whether a prospective study is truly non
interventional. This is a crucial distinction given the regulatory requirements of interventional
studies. An error in making the assumption of non intervention can have a negative impact on
the EBMT and it is advisable that protocols for planned non interventional studies are seen
by an independent reviewer. For that reason and until further notice all protocols should be
sent to Prof. Per Ljungman and Dr. Carmen Ruiz de Elvira as soon as possible after WP
approval and before any implementation is initiated.
3.2.2.1 Non interventional prospective studies versus retrospective studies
The main advantage of a prospective study is that the selection of patients is done a
priori, following a certain eligibility criteria, with the potential to follow them until the end
of the study. With retrospective studies, the investigator cannot assess the selection bias
because s/he does not know which patients will be missing from his/her study (lost to follow
up, not registered, etc.). S/he only knows of the patients that are present at the moment in
which the study is initiated. With a prospective non interventional study the bias due to
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 5
patient selection by unknown circumstances may not be completely prevented, but because
the characteristics of all patients participating in the study are known from the beginning, the
investigator will know which type of patients have been lost to the study or have poor data
and will have a better idea of how inclusive the conclusions of the study can be.
In addition, as the data are collected in real time, it is possible to collect additional data
(data not in the MED A or B forms) without urging the participating centres to go back to
their files.
3.2.2.2 Non interventional prospective studies versus clinical trials
Non interventional prospective studies cannot be compared to clinical trials and cannot
be used as a substitute for them. The aims are completely different since clinical trials aim at
testing or comparing one or more treatments or other procedures in a controlled environment,
while non interventional prospective studies can only control the selected population while
any other procedures must follow the routine of the participating centres (non-interventional).
3.2.2.3 Data collection in non interventional prospective studies
Although by definition, prospective studies will always collect data in the future, they
may also use data that has already been gathered and is stored in the registry. Whether this is
true or not, if all or part of the data collected forms part of the Med-B set of items, these data
must be stored in the Registry database.
4 Procedures for Registry studies
It is the responsibility of the EBMT Study coordinators to ensure that the correct
EBMT procedures for data management are followed. The ultimate responsibility will lie
with the head of the WP. It is advisable that all proposed studies are clearly listed under the
WP web pages.
4.1 Initiator
Any active member of the EBMT can initiate a study. An active member is any
investigator belonging to a centre that submits data to the EBMT. Usually the investigator
will belong to a WP running the study. If this is not obvious and an investigator wants to use
the EBMT database or the EBMT research infrastructure, the request will be forwarded to the
Head of the Registry. The Head of the Registry will then suggest a WP that will have the
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 6
main responsibility for the study and forward the proposal to the WP chairperson for
approval. The choice of WP will depend on the study population and its main objectives. If
the choice is not clear, the Head of the Registry will consult the Board.
4.2 Concept
Once a WP has been identified, the investigator should approach the head of that WP
with a brief description or concept of the study. This concept should contain a brief outline:
objectives, eligibility, endpoints, number of patients, an estimate of the duration of the data
collection period, an estimate of the duration of the enrolment period if the study is
prospective, and budget availability, if applicable.
The WP should verify that a similar study is not being conducted already, discuss its
scientific validity, consider the availability of resources necessary to run it and either reject or
accept the concept. If the study is accepted, the investigator will be asked to submit the final
protocol. At this point the study should be given a unique study number within the
responsible WP.
4.2.1 Inter WP studies
Once the concept has been accepted by the WP chair and if the population of the study
can be considered to be the remit of more than one WP or Committee, the investigators need
to approach the heads of those groups and request their collaboration. Once all permissions
are in place, the name, number, principal investigators, contact names for all WPs or
committees involved, and the name of the study coordinator in charge of the data
management need to be registered with the Registry Office.
The Registry Office keeps an “Inter WP Study” file which will be distributed regularly
to the Board. This should ensure that information is widely distributed to avoid similar
studies being performed by more than one WP and the Clinical Trials group.
4.3 Study protocol
Studies should not be initiated until a detailed protocol has been written, submitted to,
and approved by the WP. Once approved, the protocol should not be changed without
informing the participating centres. The protocol should include the following points:
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 7
4.3.1 Population
The characteristics of the population should be described unambiguously: diagnosis,
age, disease characteristics, transplant specifics, period, gender, etc. For example, female
patients aged between 10 and 17 at time of transplant, receiving an allogeneic transplant
between 1985 and 1990 for a non-malignant disease, and surviving a minimum of 10 years
from date of transplant.
4.3.2 Objective
The objectives of the study and its main end points (overall survival, late effects,
development of complications, etc.) should be listed and defined statistically. For example,
the aim of the study could be the effects on reproductive capability for the above population,
with the main end point being the frequency of live births at a certain point in time.
4.3.3 Variables
The protocol should be accompanied by a list of variables (items, "database fields")
that are essential for the study to be completed. This point is very important and should be
thought out carefully. Given the characteristics of registry data a balance needs to be reached
regarding the size of the population that will be available and the degree of completeness that
can be achieved for each piece of data. Variables should be divided between MED-B
variables (fields already present in the EBMT database) and MED-C variables (variables
which will need addition of fields to the database or which may need to be stored separately).
4.3.4 Participants
For some studies, either for convenience or for other reasons, it may be advisable to
restrict the number of participating centres. If this is the case, those centres should be listed at
this point, either nominally or by characteristics. For example, all centres that perform more
than 10 allografts per year for non-malignant diseases.
In some cases, the participants cannot be known because the study is based on
information that has not been stored in the Registry. An example would be a small case series
of rare complications where the patients are first identified by a question to the centre, using
a questionnaire thereafter to collect the necessary data. In this case, the protocol rather than
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 8
the centre criteria should indicate how the participants for the first question to the centres will
be selected.
4.3.4.1 Centre eligibility for non interventional prospective studies
It is advisable that the protocol for non interventional prospective studies has a
paragraph on centre eligibility. The eligibility criteria should ask the centre to confirm that
the patient management, including all the investigations deemed necessary to collect data for
the study, form part of the centre’s routine. Centres that can only participate in the study by
changing their patient management must be excluded.
4.3.5 Ethical committee approval
For a registry based study, ethical approval is generally not necessary but in some cases
ethical approval may be needed depending on country and on the design of the individual
study. It is beyond the possibility of the EBMT to have expert knowledge about the
regulations in each country. It is therefore the responsibility of the WP chair to ascertain that
investigators are aware that a registry based study might require ethical approval and that the
responsibility rests with the local investigator. It is therefore advisable that the protocol
includes a section making the hospitals aware that they may have to apply for ethical
approval under their own rules. One option could be to apply at one major centre and use that
centre’s approval for the entire study.
If sensitive information is being analysed (results of DNA analyses, for example),
ethical committee application is strongly recommended and it will be obligatory in some
countries.
4.3.6 Patient consent
For patient data to be collected by the EBMT, patient consent must have been obtained.
All EBMT members submitting data to the Registry must have a procedure for obtaining
patient consent for this purpose. It is highly likely that this consent is sufficient to cover most
cases of registry based studies. However, because this consent may be worded in different
ways in different centres, it is advisable that the protocol includes a section making the
hospitals aware that they need to check whether they would need additional patient consent to
forward the necessary data.
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 9
4.3.7 Time frame
A time frame for the conduct of the study should be included in the protocol,
indicating when the data collection will start, when it will end and the approximate date for
the publication of the results. This is particularly important for the observational studies, for
which the number of patients to be recruited and the period of recruitment must be indicated.
4.3.8 Statistics
A description of the statistical techniques which will be used to analyse the data should
be given (see the “Statistical guidelines” document and 6.0 below). This should include
grouping of variable codes, if applicable, and a clear explanation on how missing values will
be dealt with. A study statistician should be appointed at this point.
4.3.9 Authors
The authorship of the projected publication must follow the published EBMT
guidelines (see below). The study protocol should list authors such as the promoter of the
study, the statistician, pathologist, or any other investigator whose authorship will not be
dependent on the number of patients provided for the study.
4.4 Preliminary analysis
Although each WP may have different ways of dealing with studies, it is advisable that
a description of the population as it already exists in the EBMT database be produced as a
first step. An important question to consider before a study is initiated is to document the
completeness of the MED-B variables to be asked for. This is helpful to obtain an idea of the
feasibility of the study, the likely statistical power of the investigation, and, in the case of a
retrospective study, the amount of work necessary to fill in the missing data.
5 Administration
5.1 Staffing
A study coordinator and statistician should be allocated to the study. The need for staff
time should be calculated early in the preparation of the study. If the WPs or Committees
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 10
involved do not have resources to cover the study, any additional staffing requirements should
be requested through EBMT standard procedures and no staff can be recruited without central
approval. It must be noted that non interventional prospective studies will be more labour
intensive during the data collection period, but may need less work regarding the cleaning of
the data.
5.2 Documentation
The study coordinator and statistician will collaborate with the principal investigator to
develop the background and summary of the study, inclusion criteria (exclusion criteria),
registration forms, letter of introduction, data collection forms (MED C, if necessary) and
patient informed consent forms. It is important that the latter be mentioned in the introduction
letter, giving the centre the possibility of making a decision as to whether it would be
required according to each centre’s procedures.
5.3 Budget
A study can be financed either internally through the WP budget allocated by the
EBMT board or through external funding. The costs should be calculated early on and should
be ready before the protocol is finalised.
A budget should at a minimum consider the following items:
- Project management/study coordination (investigator meetings, conference calls)
- Central data management
- A per patient fee (if applicable), with an estimation of the expected number of patients
- Costs for quality assurance audit and overhead (10%).
- Statistics
5.3.1 External funding
EBMT procedures must be followed if external funding is sought. The investigator
should refer to the EBMT Treasurer for advice.
5.4 Insurance
Additional insurance is not needed for a non interventional study. If in doubt, the
investigator should turn to the Clinical Trials group for advice.
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 11
6 Data collection
Requesting data from centres should aim at obtaining the most accurate data in the
shortest possible time and with the least possible disruption to the activities of the centre
providing the data. For this reason it is important that the protocol is clear and unambiguous
regarding the patient population, that the number of data items requested is small, and that
centres are not requested to provide data which they have already provided in the past. The
Registry, in collaboration with national registries and EBMT study coordinators, has set up a
series of rules and guidelines which are described below and which should be followed by all
investigators.
6.1 Data collection and integrated National Registries
A large percentage of the data collected in the EBMT Registry is done so through the
help of National Registries which have integrated themselves within the EBMT framework.
National registries are comfortable with the EBMT approaching centres directly but
would like to be kept informed of the studies that their centres are requested to participate in.
6.2 Centre availability
Most studies will require extra data to be collected, sometimes prospectively and
sometimes retrospectively. The study coordinator will isolate those centres that are eligible
for the study (are known to contain the study population) and may be interested to participate
and will approach them either directly.
In some cases centre eligibility cannot be ascertained before approaching the centre.
This happens if the study aims to study patients which have been or will be submitted to
certain procedures, or if the study population includes patients with rare diseases which may
be registered in the Registry under a more generic disease category. Centre eligibility will
then need to be ascertained at the same time as centre availability.
All centres need to be approached in the first instance with a copy of the protocol and a
“Study page” or “Centre Registration form”. This should include:
the name and CIC of the centre
WP or Committee responsible for the study
the name of the study
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 12
population to be studied / criteria for patient eligibility
if applicable, centre eligibility by including a question on whether the centre manages
the population to be studied
the likely deadline for submission of the data
the question as to whether they are willing to participate in the study either by
filling in additional information for retrospective studies
by recruiting patients into a non interventional prospective study
request for contact details of the centre’s coordinator for this study
request for signature and dating of the form by the centre’s principal invest igator
contact details of WP or Committee study coordinator to whom Study page or
Registration form should be returned
In all cases where the centre belongs to a National Registry a copy of the protocol and
the “Study page” or “Registration form” described above should always be forwarded to the
national registries
The centre should return the “Study page” with the answer by fax, e-mail or post.
Centres who respond negatively to this request should not be approached again. At the end of
this document you can find a template for this type of document, taken from an original
provided by the ALWP.
6.3 Forms for data collection
It is highly recommended that the preparation of these forms be done with the direct
input of a study coordinator who is familiar with the EBMT database.
If variables are not yet present in the EBMT database, every attempt should be made to
keep these new items to a minimum. A list of these items should be sent to the Registry
Office to verify that these fields indeed do not exist, since the investigator may be unaware of
fields which are present in the database but used only for a particular disease. If the items are
not present, a MED-C form specific to the study can be designed. This form should not
include any of the variables already included in the existing MED-B forms, and should try to
follow its style and format. It is advisable to request the advice of the Registry Office, which
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 13
can check whether similar forms have been prepared by other WPs in the past, advice on how
best to achieve uniformity and check that there is no overlap with existing forms. To allow the
Registry Office to perform this role it is necessary this office receive copies of all study
forms. This will also help in transferring MED-C variables to MED-B forms if this request is
made in the future. If a MED-C form is unnecessary, the existing MED-B forms should be
used with minimum modification. It has to be understood that the time consumed in data entry
is proportional to the amount of changes done to the Med-B Forms.
6.4 Existing data
In most cases, retrospective studies will be dependent on existing data even if it is only
for minimum registration or transplant details. This may also be the case for some
observational studies if the events to be studied were to occur after transplant. In all cases, the
investigators have to be aware of how to deal with existing data.
Data which has already been submitted should never be requested again. For this
reason it is important that study coordinators have a clear understanding of the backlog of
data waiting to be entered. It is insufficient to ask the centres to “ignore the request if data
has been sent recently”. This only adds to the confusion and increases the workload for the
centre and for the EBMT, especially when it is discovered months later that the submitted
data still has missing information and therefore a further request may need to be made.
The registrations needed for the analysis should be identified and the backlog for these
registrations should be dealt with before requesting any more data.
Once all the backlog data has been entered, the existing data should be downloaded
from the EBMT database and processed into a format that will allow centres to see clearly
which items are missing and are, therefore, to be submitted. This only needs to be done for
those centres that do not enter data directly into the EBMT database. More details on how
best to approach centres depending on whether or not they do their own data entry will be
given below.
6.5 Requesting data
Data should be requested from centres that have responded positively to the availability
request (see above)
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 14
6.5.1 Requesting data from centres not performing data entry directly into the EBMT database
Regardless of the organisation in charge of sending the data collection request, this
should be done in the following way: The centre should receive the data collection forms or
an Excel version of it. If applicable, these forms should be filled with the data already
available in the EBMT database. The data collection forms can be sent electronically, by fax
to a secure number or by post. Electronic submission must always be done with password
protected files.
If missing data is requested, the centre should be given a reasonable deadline to
complete it. After completion, the centre should be asked to return the forms by any of the
means above to the EBMT.
If the data is requested prospectively, the centre should be in possession of a clear
schedule of when forms are due. It would be advisable that the study coordinator takes on the
responsibility of warning the centres when forms are due or overdue. This is important for
non interventional prospective studies since otherwise the advantages of prospectively
collecting data would disappear.
6.5.2 Requesting data from centres performing data entry directly into the EBMT database
Regardless of the organisation in charge of sending the data collection request, this
should be done in the following way:
6.5.2.1 Retrospective data
The centre should be provided with a list of the registrations (UICs) and asked to fill in
the relevant MED-B through ProMISe. If a MED-C form is involved, this should be sent,
filled with the necessary data to identify each registration (UIC, UPN, date of birth, date of
transplant, etc.) already available in the EBMT database. The request to fill in the MED-B
form, and the MED-C forms can be sent electronically, by fax to a secure number or by post.
Electronic submission must always be done with password protected files. The centre should
be given a reasonable deadline to complete it. After completion, the centre should return the
MED-C form, by any of the means above to the EBMT, informing them at the same time that
the MED-B data has already been entered. If there is no MED-C the centre should simply
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 15
inform the EBMT when the data has been fully entered. Electronic submission must always
be done with password protected files.
6.5.2.2 Prospective data
Centres should be asked to enter all prospective data if the fields are available in the
Registry. If the non interventional prospective study requires the registration of new patients
and/or transplants, the centre should register these patients/transplants following the standard
procedures and add the necessary data as required by the observational study protocol.
If a MED-C form is involved and the patient is already registered, this should be sent to
the centre, filled with the necessary data to identify each registration (UIC, UPN, date of
birth, date of transplant, etc.) already available in the EBMT database. If the Med-C will refer
to non existent registrations, the centre should receive an empty Med-C form which they can
reproduce for each new registration.
The request to fill in the MED-B form and the MED-C forms can be sent electronically,
by fax to a secure number or by post. Electronic submission must always be done with
password protected files if the documents contain patient data.
The centre should have a clear schedule for when these forms should be filled in and
submitted. Submission can be done by any of the means above, informing the EBMT at the
same time that the MED-B data has already been entered.
Electronic submission of Med-C data must always be done with password protected
files.
6.6 Entering data
All MED-B data must be entered into the EBMT database via ProMISe. There are no
exceptions to this rule. Keeping MED-B data outside the EBMT database in local databases
or other types of files is not acceptable and it will not be uploaded into the EBMT database if
this rule is not adhered to.
Regarding data that cannot currently be collected in the EBMT database due to absence
of appropriate fields i.e. the MED-C form, a list of these variables should be sent to the
Registry Office. Depending on the number and type of fields, these variables may be
implemented within a reasonable period of time. If they cannot be implemented, advice can
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 16
be sought on how to deal with these variables. On request, the Registry Office can create a
study project encompassing the study population within the EBMT database and provide data
entry and statistical access to those individuals dealing with this study as requested. Note that
adding specific navigation for studies cannot be done. For this reason, it is advisable that all
study forms dealing with Med-B items follow as much as possible the format of the existing
Med-B forms.
Data entry should be performed by the centres or by the EBMT. The same applies for
non interventional prospective studies. (Any additional data that is not part of MED-B can be
mailed to the relevant Study Coordinators).
Occasionally, other members of the WP or Committee may want to chase the data
themselves, or even do the data entry. If this is the case they should:
a) Consult the best way of doing this with their study coordinator or with the Registry
Office. The rules listed above on requesting data must be followed.
b) Agree with the responsible EBMT data managers/study coordinators on the allocation
of responsibilities for data entry.
c) send a ProMISe data access request form to the Registry Office, signed by the head of
the WP indicating what type of access they need (download only or data entry).
d) Ensure the data protection laws of the EU will be implemented if these members are
located outside the EU.
IMPORTANT NOTE:
Data entry should not be done by individuals who have not been properly trained.
7 Procedures for statistical analysis of Registry studies.
The EBMT has published guidelines on how statistical analysis should be performed
(Bone Marrow Transplantation, 48: S1-S37, 2013). In all proposals for Registry studies, a
plan for the statistical analysis to be performed needs to be included. With the exception of
studies for which very simple statistical analyses are intended, it is strongly recommended
that an EBMT statistician perform or at least supervise the analyses. If the analysis will not
be performed by an EBMT approved statistician, it is advisable that the analysis plan, as
detailed in the protocol, is reviewed and approved by an EBMT statistician before the
analysis is done. This plan shall include the intended methodology in enough detail so that it
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 17
can be assessed. No study should be published in the name of the EBMT unless such a
review has been performed.
8 Authorship and acknowledgement guidelines
The EBMT has issued authorship guidelines which are incorporated into the Operational
Manual under the title Authorship guidelines for EBMT publications. These guidelines should
be followed on publication of the Registry study.
Several journals now require listings of all WP-members as an appendix to submitted
papers. It may be impossible to include investigators from all participating centres in an
appendix to submitted papers. One recommended procedure is to list all members that
regularly participate in WP-activities in such a list. It is the responsibility of the WP
chairperson to collate such a list.
9 Requesting data from centres in countries with national registries.
National registries have agreed that during the course of the studies all contact can be
made directly between the EBMT and their corresponding centres, however copies of the
study protocol and “Study page” or “Registration form” should be forwarded to the national
registries before centres are contacted together with a list of those centres. These national
registries are willing to help the EBMT with contact information regarding their centres if so
requested by the EBMT.
Centres should either send data directly to the EBMT or, if entering it directly into the
EBMT database, contact the EBMT directly once they have finished with data entry. This is
true for both retrospective and prospective studies.
10 Step by step procedure
10.1 First step: requesting participation
10.1.1 Documents needed
a) A ”Study page” or ”Registration Form” requesting participation form (see 10.4 below)
b) A cover letter with an explanation of the study
c) The study protocol or synopsis
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 18
d) The number of patients likely to be involved in this centre. If the patients are known, it
would be helpful to send a list of the patients. This list must either be anonymised
(only UICs) or it must be password protected.
e) Give a deadline (recommended deadline no more than 3 to 4 weeks, see figure below)
10.1.2 Sending documents
a) To all centres: Send e-mail to the Principal Investigator (PI) asking the centre to
participate in the study. If you know who the physician likely to participate in the
centre is and it is not the PI, you can e-mail him/her directly, but the e-mail must
always be copied to the PI. The e-mail should also be always copied to the data
manager(s) of the centre.
To national registries: Send a copy of the protocol with an indication that the centres will
be contacted about this study.
10.1.3 Following up participation request
a) If the mail bounces, send it to the next physician in the on-line membership list.
Alternatively, phone the centre and request a correct e-mail address. If you do the
latter, and there is a national registry, contact the national registry first since they may
have a more updated list of contact numbers and addresses.
b) If there is no reply, repeat the request at least twice. You can:
a. send the request to other physicians
b. the WP investigator in charge of the study can contact directly (phone, e-mail,
face to face meeting, etc.) the centre physician who is most likely to be
interested in the study
c) If the centre answers negatively, stop
d) If the centre answers positively, proceed with requesting the data
10.2 Second step: requesting data
10.2.1 Sending data request
a) For all centres: Mail the contact person indicated in the "participation form" with:
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 19
10.2.1.1 Retrospective data, including data needed for non interventional prospective
studies
a. The data to be completed in Word or Excel format
b. A deadline (recommended deadline no more than 10 to 12 weeks, see figure in
10.5.1)
10.2.1.2 Prospective data
For prospective data, requests should be sent directly to the centres.
a. The forms to be submitted prospectively with the corresponding schedule
b. A deadline for each of the forms (see figure in 10.5.2)
10.2.2 Following up data request
a) If there is no reply,
repeat the request at least twice;
the WP investigator or study coordinator in charge of the study can contact directly
(phone, e-mail, meeting, etc.) the centre physician who has agreed to participate in
the study
b) On receipt of data
Thank the centre directly
10.3 Study completion
Always inform the participating centres and associated national registries when the
study has been submitted for publication.
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 20
10.4 Study page examples
10.4.1 Retrospective study
Emmanuelle Polge, ALWP
EBMT XXXWP(s)
PARTICIPATION FORM
1. Name of the study
Title
2. Centre
Centre
Name
CIC
Physician in charge of the study in the centre (If applicable, this would be the author in any publication that follows from this study. See Authorship Guidelines for EBMT
publications)
Name:
E mail :
Data manager in charge of collecting data
Name:
Tel :
E mail :
3. Deadlines
Deadline for agreement :
Deadline for data collection :
4. Participation
Are you willing to fill in additional information, and to complete Med B information for the study?
YES* NO
* the study specific questionnaire will be sent at reception of the completed “Participation form”
Pease reply before deadline for agreement to: Name of study coordinator : {postal address : {-mail address}
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 21
: {fax number}
10.4.2 Non interventional prospective study
Anja van Biezen, CMWP
[Study] CENTRE REGISTRATION
Study
[Study Title]
Centre eligibility criteria (examples):
Do you routinely do [procedure] for [diagnosis] in [population]? Yes
Is administration of [drug] and [drug] part of your standard treatment for [diagnosis]? Yes
Is [type] HSCT a standard option for [diagnosis] in your centre? Yes
Do you perform follow ups routinely every [number] months after the [type] HSCT? Yes You must answer Yes to all questions in order to participate in this study.
Centre EBMT Centre Identification Code (CIC) ..................................................................................... Centre Address .................................................................................. ..................................................................................... Physician in charge of the study in the centre .....................................................................................
(If applicable, this would be the author in any publication that follows from this study. See Authorship Guidelines for EBMT
publications)
Email address ..................................................................................... Does your centre want to participate in this non-interventional prospective study?
No reason:…………………….………………………………………………
Yes
How many patients do you expect to include in this study per year? I_I_I Proposed Start Date: ............... - ........ ........ - ........ ........ ........ ........ dd mm yyyy
IDENTIFICATION & SIGNATURE When participating: I agree to include all consecutive patients who agree to participate in this study and declare that the inclusion of any patient in this study will not affect the management of this patient.
.............................................................................................................................................................................. Signature
............................................................................................................................................................................... Name
Please send the completed form to the [office] asap by using Fax: [fax number] or E-mail: [email address]
[Full Office Contact Details]
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 22
10.5 Recommended flow and deadlines
10.5.1 Retrospective studies
Emmanuelle Polge (ALWP), and Rosi Oneto, (SAAWP)
Reminder for Agreement
1st contact
Deadline for Data
Collection
Deadline for
Agreement
Reminder for Data
Collection
0 12 W
14 W 20 W
End for Data
Collection
5-6 W
3-4 W
CONDUCT OF REGISTRY STUDIES
Last modified: 26/05/15 Page 23
10.5.2 Non interventional prospective studies
Marijke Scholten (CMWP)
Data Flow
Data Flow per patient